Analysts Rally Behind Waystar: Predict Robust Growth and Market Share Gains Following Competitor Setback
Analysts Rally Behind Waystar: Predict Robust Growth and Market Share Gains Following Competitor Setback
In response to the Change disruption in February, Waystar launched a program for impacted providers to expedite access to its platform within 2-3 days of contract execution.BofA Securities analyst Allen Lutz initiated coverage on Waystar Holding Corp. (NASDAQ:WAY) with a Buy rating and price forecast of $27.
BofA Securities分析師Allen Lutz發表評論，將Waystar Holding Corp. (NASDAQ:WAY)評級爲“買入”，目標價爲27美元。
According to Lutz, Waystar is well positioned for 10% revenue growth supported by steady end-market demand and recent competitive changes.
根據Lutz的說法，Waystar因市場需求穩定和近期競爭變化的支持而處於良好位置，將實現10%的營收增長。
In addition, the cybersecurity attack on competitor Change Healthcare could drive Waystar's market share gains.
此外，Change Healthcare的網絡安全攻擊可能會推動Waystar的市場份額增長。
In response to the Change disruption in February, Waystar launched a program for impacted providers to expedite access to its platform within 2-3 days of contract execution.
針對2月份發生的Change干擾，Waystar推出了一個計劃，以便受影響的提供商在合同簽訂後2-3天內快速訪問其平台。
The company initially added 30K provider customers and could add more over the next few quarters, the analyst adds.
分析師補充道，公司最初增加了3萬個服務商客戶，未來幾個季度可能會增加更多客戶。
Waystar operates in a $15 billion market, with stable ~40% margins over the next three years. Precisely, the company has a solid opportunity to expand its existing relationships with 18 of the top 22 hospitals and potential changes in the competitive environment can support further growth.
Waystar在150億美元的市場中運營，在未來三年內有着穩定的40%利潤率。公司與前22家醫院中的18家已經建立了很好的關係，未來的競爭環境變化有助於進一步增長。
Over time, Lutz projects a structural shift in health systems, reducing dependence on Change by diversifying with independent vendors to guard against future cyber breaches. The analyst projects FY24 EPS of $0.20.
隨着時間的推移，Lutz預計衛生系統將出現結構性轉變，通過與獨立供應商組合減少對Change的依賴，以防止未來的網絡安全漏洞。分析師預測FY24每股收益爲0.20美元。
Goldman Sachs analyst Adam Hotchkiss initiated coverage on Waystar with a Buy rating and a $32 price forecast.
高盛分析師Adam Hotchkiss將Waystar評級爲“買入”，目標價爲32美元。
Per Hotchkiss, Waystar's comprehensive technology platform, addressing multiple points across the healthcare revenue cycle, is unique within a market dominated by point-solution technology vendors, manual processes, and healthcare IT services businesses.
Hotchkiss指出，Waystar的全面技術平台，在衛生保健收入週期的多個關鍵點進行了解決，這在由點解決方案技術供應商、手動流程和衛生保健IT服務企業主導的市場中是獨一無二的。
The analyst adds that Waystar's deliberate combination of assets drives a more compelling sale to and partnership with larger hospitals and health systems. The analyst projects FY24 EPS of $0.21.
分析師補充道，Waystar的資產有意地結合起來，向大型醫院和衛生系統提出了更具吸引力的銷售和合作。分析師預測FY24每股收益爲0.21美元。
William Blair analyst Ryan Daniels initiates coverage on Waystar Holding with an Outperform rating.
William Blair分析師Ryan Daniels將Waystar Holding評級爲“跑贏大盤”（Outperform）。
For fiscal 2024, the analyst projects total revenue of $885 million, adjusted EBITDA of $351 million, and adjusted earnings per share of $0.19.
對於2024財年，分析師預計總收入爲8.85億美元，調整後的EBITDA爲3.51億美元，調整後的每股收益爲0.19美元。
For fiscal 2025, Daniels projects revenue of $971 million, adjusted EBITDA of $380 million, and adjusted earnings per share of $0.69.
對於2025財年，Daniels預計收入爲9.71億美元，調整後的EBITDA爲3.8億美元，調整後的每股收益爲0.69美元。
Price Action: WAY shares are trading higher by 0.46% to $21.61 at last check Tuesday.
股票價格行情：在上週二最後一次檢查時，WAY股票價格上漲了0.46%，達到21.61美元。
Image via Dall-E 3
圖像通過Dall-E 3
